Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Treating Metastatic Hormone Refractory Prostate Cancer - My Approach
Prostate Cancer Published 1 year ago
ASCO Genitourinary Cancers Symposium– Your Top Takeways for Prostate Cancer
Prostate Cancer Published 1 year ago
Content
Prostate Cancer
5m 3s
Importance of using life extending therapy in Metastatic Castration-Sensitive Prostate Cancer
Published 11 Jul 2022
Metastatic Castration Sensitive Prostate (mCSPC) Cancer has seen paradigm change in treatment options. Though Androgen Deprivation Therapy (ADT) is useful , patients ultimately develop castration resistant disease. It is important to choose right treatment option in mCSPC phase to delay the development of Castration Resistant Prostate Cancer (mCRPC). Abiraterone , Enzalutamide & Apalutamide have shown efficacy in mCSPC. International treatment guidelines recommend treatment intensification with ADT + Docetaxel or ADT + Androgen receptor targeted drugs for Denovo mCSPC.
